INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,259,167 | +134.8% | 62,568 | +185.5% | 0.00% | +100.0% |
| Q2 2023 | $1,387,911 | -49.2% | 21,919 | -56.6% | 0.00% | -33.3% |
| Q1 2023 | $2,734,304 | +64.0% | 50,495 | +60.3% | 0.00% | +50.0% |
| Q4 2022 | $1,666,874 | -62.9% | 31,498 | -67.3% | 0.00% | -66.7% |
| Q3 2022 | $4,488,000 | -27.1% | 96,455 | -10.6% | 0.01% | -25.0% |
| Q2 2022 | $6,158,000 | +3.1% | 107,882 | +10.5% | 0.01% | +33.3% |
| Q1 2022 | $5,973,000 | +94.0% | 97,609 | +65.9% | 0.01% | +100.0% |
| Q4 2021 | $3,079,000 | -25.0% | 58,823 | -46.6% | 0.00% | -25.0% |
| Q3 2021 | $4,105,000 | +93.4% | 110,105 | +111.7% | 0.00% | +100.0% |
| Q2 2021 | $2,123,000 | +674.8% | 52,003 | +115.9% | 0.00% | +100.0% |
| Q4 2018 | $274,000 | – | 24,087 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
| EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
| Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
| Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
| SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
| GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
| BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
| Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
| Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
| Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |